People · Operator
Named in public records as an officer, director or promoter · active 2012–2014 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pearl Therapeutics Inc | — | Pharmaceuticals | Series B | $74.0M | $791.4M | 2012 |
| ImmusanT, Inc. | — | Biotechnology | Series B | $32.7M | $788.8M | 2014 |
Sundar Kodiyalam at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sundar Kodiyalam on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Howard Rosen | 1 | 5 |
| James Young | 1 | 4 |
| Thomas Daniel | 1 | 4 |
| Howard B. Rosen | 1 | 4 |
| JAMES W. YOUNG | 1 | 3 |
| Sarvajna Dwivedi | 1 | 2 |
| Kevin Ferro | 1 | 2 |
| Kathy LaPorte | 1 | 2 |
| Nicholas J. Simon | 1 | 2 |
| Thomas Koestler | 1 | 2 |
| Michael Golden | 1 | 2 |
| Kevin B. Ferro | 1 | 1 |
| Sundar Kodijalam | 1 | 1 |
| Nicholas Simon | 1 | 1 |
| Craig Estwick | 1 | 1 |
| Justin Sun | 1 | 1 |
| Leslie Williams | 1 | 1 |
| Ceclia Gonzalo | 1 | 1 |
| Charles Bramlage | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.